{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T00:06:18Z","timestamp":1747181178523,"version":"3.40.5"},"reference-count":33,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"10","license":[{"start":{"date-parts":[[2023,3,10]],"date-time":"2023-03-10T00:00:00Z","timestamp":1678406400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,3,10]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>The global prevalence of type 2 diabetes mellitus (T2DM) is growing yearly. The efficacy of ertugliflozin (ERT), a recently licensed anti-diabetic drug, has been widely reported. However, additional evidence-based data is required to ensure its safety. In particular, convincing evidence on the effects of ERT on renal function and cardiovascular outcomes is needed.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>We searched PubMed, Cochrane Library, Embase, and Web of Science for randomized placebo-controlled trials of ERT for T2DM published up to August 11, 2022. Cardiovascular events here mainly refer to acute myocardial infarction and angina pectoris (AP) (including stable AP and unstable AP). The estimated glomerular filtration rate (eGFR) was used to measure renal function. The pooled results are risk ratios (RRs) and 95% confidence intervals (CIs). Two participants worked independently to extract data.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>We searched 1516 documents and filtered the titles, abstracts, and full text, 45 papers were left. Seven trials met the inclusion criteria and were ultimately included in the meta-analysis. The meta-analysis found that ERT reduced eGFR by 0.60 mL\u00b7min<jats:sup>\u22121<\/jats:sup>\u00b71.733 m<jats:sup>\u22122<\/jats:sup> (95% CI: \u22121.02\u2013\u22120.17, <jats:italic toggle=\"yes\">P<\/jats:italic> = .006) in patients with T2DM when used for no more than 52 weeks and these differences were statistically significant. Compared with placebo, ERT did not increase the risk of acute myocardial infarction (RR 1.00, 95% CI: 0.83\u20131.20, <jats:italic toggle=\"yes\">P<\/jats:italic> = .333) and AP (RR 0.85, 95% CI: 0.69\u20131.05, <jats:italic toggle=\"yes\">P<\/jats:italic> = .497). However, the fact that these differences were not statistically significant.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>This meta-analysis shows that ERT reduces eGFR over time in people with T2DM but is safe in the incidence of specific cardiovascular events.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000033198","type":"journal-article","created":{"date-parts":[[2023,3,10]],"date-time":"2023-03-10T17:11:27Z","timestamp":1678468287000},"page":"e33198","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":5,"title":["Effect of ertugliflozin on renal function and cardiovascular outcomes in patients with type 2 diabetes mellitus: A systematic review and meta-analysis"],"prefix":"10.1097","volume":"102","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4012-8693","authenticated-orcid":false,"given":"Qian","family":"Cheng","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shupeng","family":"Zou","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chengyang","family":"Feng","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chan","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yazheng","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuan","family":"Shi","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1556-543X","authenticated-orcid":false,"given":"Minghui","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20250504","doi-asserted-by":"crossref","first-page":"109118","DOI":"10.1016\/j.diabres.2021.109118","article-title":"IDF diabetes atlas: global estimates of undiagnosed diabetes in adults for 2021.","volume":"183","author":"Ogurtsova","year":"2021","journal-title":"Diabetes Res Clin Pract"},{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"e3109","DOI":"10.1002\/dmrr.3109","article-title":"Pharmacogenetics of type 2 diabetes mellitus, the route toward tailored medicine.","volume":"35","author":"Mannino","year":"2019","journal-title":"Diabetes Metab Res Rev"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"9704659","DOI":"10.1155\/2020\/9704659","article-title":"Safety of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with conventional therapy at different periods: a meta-analysis of randomized controlled trials.","volume":"2020","author":"Huang","year":"2020","journal-title":"J Diabetes Res"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"546","DOI":"10.3390\/medicina55090546","article-title":"From pre-diabetes to diabetes: diagnosis, treatments and translational research.","volume":"55","author":"Khan","year":"2019","journal-title":"Medicina (Kaunas)"},{"issue":"Supplement_1","key":"R5-20250504","first-page":"S144","article-title":"10. Cardiovascular disease and risk management: standards of medical care in diabetes\u20142022.","volume":"45","year":"2021","journal-title":"Diabetes Care"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1161\/CIRCULATIONAHA.120.050255","article-title":"Efficacy of ertugliflozin on heart failure-related events in patients with type 2 diabetes mellitus and established atherosclerotic cardiovascular disease: results of the VERTIS CV trial.","volume":"142","author":"Cosentino","year":"2020","journal-title":"Circulation"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMoa2004967","article-title":"Cardiovascular outcomes with ertugliflozin in type 2 diabetes.","volume":"383","author":"Cannon","year":"2020","journal-title":"N Engl J Med"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"691907","DOI":"10.3389\/fcvm.2021.691907","article-title":"Cardiovascular outcome in patients treated with SGLT2 inhibitors for heart failure: a meta-analysis.","volume":"8","author":"Gager","year":"2021","journal-title":"Front Cardiovasc Med"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"2744","DOI":"10.1161\/CIRCULATIONAHA.118.034986","article-title":"Incidence of hospitalization for heart failure and case-fatality among 3.25 million people with and without diabetes mellitus.","volume":"138","author":"Mcallister","year":"2018","journal-title":"Circulation"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1161\/CIRCULATIONAHA.114.014796","article-title":"Impact of diabetes mellitus on hospitalization for heart failure, cardiovascular events, and death: outcomes at 4 years from the Reduction of Atherothrombosis for Continued Health (REACH) registry.","volume":"132","author":"Cavender","year":"2015","journal-title":"Circulation"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1056\/NEJMc1602469","article-title":"Trends in chronic kidney disease in China.","volume":"375","author":"Zhang","year":"2016","journal-title":"N Engl J Med"},{"key":"R12-20250504","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1001\/jama.2016.10924","article-title":"Clinical manifestations of kidney disease among US adults with diabetes, 1988-2014.","volume":"316","author":"Afkarian","year":"2016","journal-title":"JAMA"},{"issue":"Suppl 1","key":"R13-20250504","first-page":"S151","article-title":"11. Microvascular complications and foot care: standards of medical care in diabetes-2021.","volume":"44","year":"2021","journal-title":"Diabetes Care"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1001\/jama.2011.861","article-title":"Temporal trends in the prevalence of diabetic kidney disease in the United States.","volume":"305","author":"de Boer","year":"2011","journal-title":"JAMA"},{"key":"R15-20250504","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1007\/s00125-011-2404-1","article-title":"Association of HbA1c levels with vascular complications and death in patients with type 2 diabetes: evidence of glycaemic thresholds.","volume":"55","author":"Zoungas","year":"2012","journal-title":"Diabetologia"},{"key":"R16-20250504","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s13300-017-0337-5","article-title":"Ertugliflozin in patients with stage 3 chronic kidney disease and type 2 diabetes mellitus: the VERTIS RENAL randomized study.","volume":"9","author":"Grunberger","year":"2018","journal-title":"Diabetes Ther"},{"key":"R17-20250504","doi-asserted-by":"crossref","first-page":"175394472110026","DOI":"10.1177\/17539447211002678","article-title":"The dawn of the four-drug era? SGLT2 inhibition in heart failure with reduced ejection fraction.","volume":"15","author":"Genuardi","year":"2021","journal-title":"Therapeutic Advances in Cardiovascular Disease"},{"key":"R18-20250504","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1111\/dom.13681","article-title":"Safety and efficacy of ertugliflozin in Asian patients with type 2 diabetes mellitus inadequately controlled with metformin monotherapy: VERTIS Asia.","volume":"21","author":"Ji","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"R19-20250504","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1111\/dom.13116","article-title":"Efficacy and safety of the addition of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sitagliptin: the VERTIS SITA2 placebo-controlled randomized study.","volume":"20","author":"Dagogo-Jack","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"R20-20250504","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/bmjdrc-2021-002484","article-title":"Glycemic efficacy and safety of the SGLT2 inhibitor ertugliflozin in patients with type 2 diabetes and stage 3 chronic kidney disease: an analysis from the VERTIS CV randomized trial.","volume":"9","author":"Dagogo-Jack","year":"2021","journal-title":"BMJ Open Diabetes Res Care"},{"key":"R21-20250504","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1111\/dom.12486","article-title":"Blood pressure-lowering effect of the sodium glucose co-transporter-2 inhibitor ertugliflozin, assessed via ambulatory blood pressure monitoring in patients with type 2 diabetes and hypertension.","volume":"17","author":"Amin","year":"2015","journal-title":"Diabetes Obes Metab"},{"key":"R22-20250504","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1111\/dom.12888","article-title":"Phase III, efficacy and safety study of ertugliflozin monotherapy in people with type 2 diabetes mellitus inadequately controlled with diet and exercise alone.","volume":"19","author":"Terra","year":"2017","journal-title":"Diabetes Obes Metab"},{"key":"R23-20250504","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s13300-017-0358-0","article-title":"Ertugliflozin and sitagliptin co-initiation in patients with type 2 diabetes: the VERTIS SITA randomized study.","volume":"9","author":"Miller","year":"2018","journal-title":"Diabetes Ther"},{"key":"R24-20250504","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1111\/dom.13631","article-title":"Long-term efficacy and safety of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin monotherapy: 104-week VERTIS MET trial.","volume":"21","author":"Gallo","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"R25-20250504","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1007\/s00125-021-05407-5","article-title":"Effects of ertugliflozin on kidney composite outcomes, renal function and albuminuria in patients with type 2 diabetes mellitus: an analysis from the randomised VERTIS CV trial.","volume":"64","author":"Cherney","year":"2021","journal-title":"Diabetologia"},{"key":"R26-20250504","doi-asserted-by":"crossref","first-page":"108744","DOI":"10.1016\/j.diabres.2021.108744","article-title":"Management of diabetic ketoacidosis in special populations.","volume":"174","author":"Eledrisi","year":"2021","journal-title":"Diabetes Res Clin Pract"},{"key":"R27-20250504","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1186\/s12933-020-01071-y","article-title":"SGLT2i: beyond the glucose-lowering effect.","volume":"19","author":"Ni","year":"2020","journal-title":"Cardiovasc Diabetol"},{"key":"R28-20250504","doi-asserted-by":"crossref","first-page":"e35","DOI":"10.34172\/jrip.2021.35","article-title":"Sodium-glucose co-transporter 2 inhibitors (SGLT2i); as a preventive factor of kidney failure in patients with type 2 diabetes; a meta-analysis of randomized controlled trials.","volume":"10","author":"Jahangiri","year":"2021","journal-title":"J Ren Inj Prev"},{"key":"R29-20250504","doi-asserted-by":"crossref","first-page":"E45","DOI":"10.2337\/dc20-2265","article-title":"Changes in cardiovascular biomarkers associated with the sodium-glucose cotransporter 2 (SGLT2) inhibitor ertugliflozin in patients with chronic kidney disease and type 2 diabetes.","volume":"44","author":"Lawler","year":"2021","journal-title":"Diabetes Care"},{"key":"R30-20250504","doi-asserted-by":"crossref","first-page":"752440","DOI":"10.3389\/fphar.2021.752440","article-title":"Efficacy and safety of ertugliflozin in type 2 diabetes: a systematic review and meta-analysis.","volume":"12","author":"Liu","year":"2022","journal-title":"Front Pharmacol"},{"key":"R31-20250504","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/hr.2016.87","article-title":"Increased cardiovascular risk of treated white coat and masked hypertension in patients with diabetes and chronic kidney disease: the HONEST Study.","volume":"40","author":"Kushiro","year":"2017","journal-title":"Hypertens Res"},{"key":"R32-20250504","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1038\/hr.2017.67","article-title":"Hypertension with diabetes mellitus: significance from an epidemiological perspective for Japanese.","volume":"40","author":"Tatsumi","year":"2017","journal-title":"Hypertens Res"},{"key":"R33-20250504","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1097\/MNH.0000000000000584","article-title":"Renal effects of SGLT2 inhibitors: an update.","volume":"29","author":"Nespoux","year":"2020","journal-title":"Curr Opin Nephrol Hypertens"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000033198","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T02:48:15Z","timestamp":1746326895000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000033198"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,10]]},"references-count":33,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000033198","relation":{},"ISSN":["0025-7974"],"issn-type":[{"type":"print","value":"0025-7974"}],"subject":[],"published":{"date-parts":[[2023,3,10]]}}}